| Symbol | INBX |
|---|---|
| Name | INHIBRX BIOSCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 11025 N. TORREY PINES ROAD,SUITE 140, CALIFORNIA, 92037, United States |
| Telephone | (858) 795-4220 |
| Fax | — |
| — | |
| Website | https://www.inhibrx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0002007919 |
| Description | We are a clinical-stage biotechnology company dedicated to helping people with life-threatening conditions through scientific innovation and excellence. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Inhibrx Biosciences, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000905148-26-002437 <b>Size:</b> 42 KB
Read more(90% Positive) INHIBRX BIOSCIENCES, INC. (INBX) Announces Enrollment Update for FOLFIRI Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreInhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
Read moreMatly David 🟢 acquired 50.0K shares (1 derivative) of Inhibrx Biosciences, Inc. (INBX) at $129.06 ($6.5M) Transaction Date: Apr 24, 2026 | Filing ID: 000002
Read moreNew Form DEFA14A - Inhibrx Biosciences, Inc. <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0002007919-26-000015 <b>Size:</b> 616 KB
Read moreNew Form DEF 14A - Inhibrx Biosciences, Inc. <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0002007919-26-000014 <b>Size:</b> 1 MB
Read moreInhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
Read more(10% Negative) INHIBRX BIOSCIENCES, INC. (INBX) Announces Delay in FOLFIRI Trials for an ORR of 20% per RECIST v1 Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read more(90% Positive) INHIBRX BIOSCIENCES, INC. (INBX) Reports Q1 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06353997 | Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC P… | Phase2 | Triple Negative Breast Cancer | Recruiting | 2024-09-05 | 2029-06-01 | ClinicalTrials.gov |
| NCT06295731 | INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC | Phase2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Active_Not_Recruiting | 2024-05-14 | 2029-05-01 | ClinicalTrials.gov |
| NCT04950075 | Study of INBRX-109 in Conventional Chondrosarcoma | Phase2 | Conventional Chondrosarcoma | Active_Not_Recruiting | 2021-09-23 | 2026-12-01 | ClinicalTrials.gov |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) … | Phase1 | Solid Tumor | Active_Not_Recruiting | 2019-12-10 | 2027-05-12 | ClinicalTrials.gov |
| NCT03815396 | Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha… | Phase1 | Alpha-1 Antitrypsin Deficiency | Completed | 2019-07-19 | 2022-08-18 | ClinicalTrials.gov |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumo… | Phase1 | Metastatic Solid Tumors | Terminated | 2019-01-30 | 2024-10-03 | ClinicalTrials.gov |
| NCT03715933 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Soli… | Phase1 | Ewing Sarcoma | Recruiting | 2018-10-08 | 2026-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Pembrolizumab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| INBRX-106 | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| Pembrolizumab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| INBRX-106 | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| Pembrolizumab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| INBRX-106 | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| Pembrolizumab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| INBRX-106 | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| Pembrolizumab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| INBRX-106 | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| INBRX-101/rhAAT-Fc | Other | Phase PHASE1 | Alpha-1 Antitrypsin Deficiency | COMPLETED | NCT03815396 |
| Pembrolizumab | Other | Phase PHASE1 | Metastatic Solid Tumors | TERMINATED | NCT03809624 |
| INBRX-105 - PDL1x41BB antibody | Other | Phase PHASE1 | Metastatic Solid Tumors | TERMINATED | NCT03809624 |
| Nab paclitaxel 100mg/m2 | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Paclitaxel 200mg/m2 | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Cisplatin 75mg/m2 | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Pemetrexed 500 mg/m2 | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Carboplatin AUC-6 | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Carboplatin AUC-5 | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| pembrolizumab 400 mg | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| pembrolizumab 200 mg | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| INBRX-106 - Hexavalent OX40 agonist antibody | Other | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Placebo | Other | Phase PHASE2 | Conventional Chondrosarcoma | ACTIVE_NOT_RECRUITING | NCT04950075 |
| INBRX-109 | Other | Phase PHASE2 | Conventional Chondrosarcoma | ACTIVE_NOT_RECRUITING | NCT04950075 |
| INBRX-106 | Other | Phase PHASE2 | Triple Negative Breast Cancer | RECRUITING | NCT06353997 |
| Pembrolizumab | Other | Phase PHASE2 | Triple Negative Breast Cancer | RECRUITING | NCT06353997 |
| Fluorouracil | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Leucovorin | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| pemetrexed | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| carboplatin | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Temozolomide | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Irinotecan | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| INBRX-109 | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Pembrolizumab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| INBRX-106 | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | ACTIVE_NOT_RECRUITING | NCT06295731 |
| INBRX-106 | DRUG | Phase PHASE2 | Triple Negative Breast Cancer | RECRUITING | NCT06353997 |
| Placebo | DRUG | Phase PHASE2 | Conventional Chondrosarcoma | ACTIVE_NOT_RECRUITING | NCT04950075 |
| Nab paclitaxel 100mg/m2 | DRUG | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Paclitaxel 200mg/m2 | DRUG | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Cisplatin 75mg/m2 | DRUG | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Pemetrexed 500 mg/m2 | DRUG | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Carboplatin AUC-6 | DRUG | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| Carboplatin AUC-5 | DRUG | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| pembrolizumab 400 mg | DRUG | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| pembrolizumab 200 mg | DRUG | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| INBRX-106 - Hexavalent OX40 agonist antibody | DRUG | Phase PHASE1 | Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04198766 |
| INBRX-101/rhAAT-Fc | DRUG | Phase PHASE1 | Alpha-1 Antitrypsin Deficiency | COMPLETED | NCT03815396 |
| Pembrolizumab | DRUG | Phase PHASE2 | Triple Negative Breast Cancer | RECRUITING | NCT06353997 |
| INBRX-105 - PDL1x41BB antibody | DRUG | Phase PHASE1 | Metastatic Solid Tumors | TERMINATED | NCT03809624 |
| Fluorouracil | DRUG | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Leucovorin | DRUG | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| pemetrexed | DRUG | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| carboplatin | DRUG | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Temozolomide | DRUG | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| Irinotecan | DRUG | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT03715933 |
| INBRX-109 | DRUG | Phase PHASE2 | Conventional Chondrosarcoma | ACTIVE_NOT_RECRUITING | NCT04950075 |